drugset / Trial / NCT04231851
CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
Phase 2
Active not recruiting
30 enrolled
University of California, Irvine
Jazz Pharmaceuticals · collabPfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 2 single-arm, open-label clinical trial determining efficacy of CPX-351 in combination with Glasdegib in subjects with Acute Myelogenous Leukemia with myelodysplastic syndrome related changes or therapy-related acute myeloid leukemia.
Timeline
- Start
- 2020-02-19
- Primary completion
- 2024-06-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CPX-351 | Other / unclassified | 29 mg/m2 | Intravenous |
| Subject | CPX-351 | Other / unclassified | 44 mg/m2 | Intravenous |
| Subject | CPX-351 | Other / unclassified | 65 mg/m2 | Intravenous |
| Subject | CPX-351 | Other / unclassified | 100 mg/m2 | Intravenous |
| Subject | Glasdegib | Small molecule | 100 mg | Oral |